CR11434A - Anticuerpos anti-amiloide humanos; composiciones, metodosy usos - Google Patents

Anticuerpos anti-amiloide humanos; composiciones, metodosy usos

Info

Publication number
CR11434A
CR11434A CR11434A CR11434A CR11434A CR 11434 A CR11434 A CR 11434A CR 11434 A CR11434 A CR 11434A CR 11434 A CR11434 A CR 11434A CR 11434 A CR11434 A CR 11434A
Authority
CR
Costa Rica
Prior art keywords
methods
human anti
compositions
amyloid
amyloid antibodies
Prior art date
Application number
CR11434A
Other languages
English (en)
Inventor
Mercken Marc
M Benson Jacqueline
S Jung Sun-Yung
Jiang Haiyan
Raghunathan Gopalan
Borozdina-Birch Lionella
Original Assignee
Centocor Inc
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centocor Inc, Janssen Pharmaceutica Nv filed Critical Centocor Inc
Publication of CR11434A publication Critical patent/CR11434A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Psychology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención se relaciona con al menos un anticuerpo anti-amiloide humano nuevo, que incluye ácidos nucleicos aislados que codifican al menos un anticuerpo anti-amiloide, amiloide, vectores, células huésped, plantas o animales transgénicos y métodos para hacer y utilizar éste, que incluyen composiciones, métodos y dispositivos terapéuticos.
CR11434A 2007-10-15 2010-05-17 Anticuerpos anti-amiloide humanos; composiciones, metodosy usos CR11434A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US97995407P 2007-10-15 2007-10-15

Publications (1)

Publication Number Publication Date
CR11434A true CR11434A (es) 2011-01-14

Family

ID=40568052

Family Applications (1)

Application Number Title Priority Date Filing Date
CR11434A CR11434A (es) 2007-10-15 2010-05-17 Anticuerpos anti-amiloide humanos; composiciones, metodosy usos

Country Status (16)

Country Link
US (1) US20100074901A1 (es)
EP (1) EP2211886A4 (es)
JP (1) JP2011500059A (es)
KR (1) KR20100075639A (es)
CN (1) CN102762220A (es)
AU (1) AU2008312611A1 (es)
CA (1) CA2703050A1 (es)
CO (1) CO6270335A2 (es)
CR (1) CR11434A (es)
EA (1) EA201070479A1 (es)
IL (1) IL204930A0 (es)
MX (1) MX2010004179A (es)
NI (1) NI201000056A (es)
SV (1) SV2010003533A (es)
WO (1) WO2009052125A2 (es)
ZA (1) ZA201003427B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101140934B1 (ko) 2010-08-05 2012-05-03 삼성전기주식회사 초음파 영상의 음속도 추정 방법 및 이를 적용한 초음파 진단 장치
WO2012109553A2 (en) * 2011-02-11 2012-08-16 Research Corporation Technologies Ch2 domain template molecules derived from rational grafting of donor loops onto ch2 scaffolds
AR085302A1 (es) 2011-02-24 2013-09-18 Sanofi Sa Metodo de produccion de anticuerpos sialilados
US8809508B2 (en) * 2011-03-16 2014-08-19 Probiodrug Ag Diagnostic antibody assay
PT3104854T (pt) 2014-02-10 2020-06-26 Respivant Sciences Gmbh Estabilizadores de mastócitos para tratamento de doença pulmonar
WO2015120389A1 (en) 2014-02-10 2015-08-13 Patara Pharma, LLC Mast cell stabilizers treatment for systemic disorders
WO2017027387A1 (en) 2015-08-07 2017-02-16 Patara Pharma, LLC Methods for the treatment of mast cell related disorders with mast cell stabilizers
WO2017027402A1 (en) 2015-08-07 2017-02-16 Patara Pharma, LLC Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders
CN106344931A (zh) * 2016-08-29 2017-01-25 苏州普罗达生物科技有限公司 一种小分子淀粉样蛋白抗体多肽与雌激素的偶联结合物
EP3506893A4 (en) 2016-08-31 2020-01-22 Respivant Sciences GmbH CROMOLYNE COMPOSITIONS FOR THE TREATMENT OF CHRONIC COUGH DUE TO IDIOPATHIC PULMONARY FIBROSIS
AU2017339366A1 (en) 2016-10-07 2019-04-11 Respivant Sciences Gmbh Cromolyn compositions for treatment of pulmonary fibrosis
GB201701404D0 (en) * 2017-01-27 2017-03-15 Micropharm Ltd Therapies for treating inflammatory disorders
EP3628009A4 (en) * 2017-05-19 2021-03-24 The Regents of The University of Colorado, A Body Corporate COMPOSITIONS AND PROCESSES FOR IMPROVING PERCEPTION
CN108704125A (zh) * 2018-06-20 2018-10-26 深圳大学 一种治疗二型糖尿病的疫苗、制备方法及应用
CN110511276A (zh) * 2019-08-13 2019-11-29 王跃驹 植物作为宿主在表达Aducanumab抗体中的应用
US20230034474A1 (en) * 2019-09-10 2023-02-02 Ac Immune Sa Novel Molecules for Diagnosis
AU2020401837A1 (en) * 2019-12-11 2022-07-21 Ambetex Pty Ltd Therapeutic compositions comprising an amyloid beta antibody or vaccine for prevention and treatment of diastolic dysfunction
CN113138276B (zh) * 2020-01-19 2022-09-16 厦门万泰凯瑞生物技术有限公司 用于检测HBcAg的方法及抗体
CN113178001B (zh) * 2021-04-01 2023-07-04 北京科技大学 面向孔源性视网膜脱离的硅油填充模拟方法及电子设备

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7179892B2 (en) * 2000-12-06 2007-02-20 Neuralab Limited Humanized antibodies that recognize beta amyloid peptide
AR038568A1 (es) * 2002-02-20 2005-01-19 Hoffmann La Roche Anticuerpos anti-a beta y su uso
WO2004029629A1 (en) * 2002-09-27 2004-04-08 Janssen Pharmaceutica N.V. N-11 truncated amyloid-beta nomoclonal antibodies, compositions, methods and uses
WO2005028511A2 (en) * 2003-03-28 2005-03-31 Centocor, Inc. Anti-amyloid antibodies, compositions, methods and uses
GEP20115195B (en) * 2004-07-30 2011-04-11 Rinat Neuroscience Corp Antibodies directed against amyloid-beta peptide and use thereof
WO2006039470A2 (en) * 2004-09-29 2006-04-13 Centocor, Inc. Anti- amyloid antibodies, compositions, methods and uses

Also Published As

Publication number Publication date
WO2009052125A9 (en) 2010-02-11
EP2211886A4 (en) 2011-07-27
ZA201003427B (en) 2011-10-26
WO2009052125A2 (en) 2009-04-23
EP2211886A2 (en) 2010-08-04
KR20100075639A (ko) 2010-07-02
CO6270335A2 (es) 2011-04-20
CA2703050A1 (en) 2009-04-23
SV2010003533A (es) 2011-01-10
MX2010004179A (es) 2010-08-04
AU2008312611A1 (en) 2009-04-23
IL204930A0 (en) 2010-11-30
US20100074901A1 (en) 2010-03-25
JP2011500059A (ja) 2011-01-06
EA201070479A1 (ru) 2010-12-30
CN102762220A (zh) 2012-10-31
NI201000056A (es) 2010-11-10

Similar Documents

Publication Publication Date Title
CR11434A (es) Anticuerpos anti-amiloide humanos; composiciones, metodosy usos
AR053470A1 (es) Anticuerpos anti -mcp-1, composiciones , metodos y usos
CR9551A (es) Anticuerpos anti-il-6, composiciones, metodos y usos
CY1121252T1 (el) Anti-il-23 αντισωματα, συνθεσεις, μεθοδοι και χρησεις
CY1118880T1 (el) Ανθρωπινα anti-il-23 αντισωματα, συνθεσεις, μεθοδοι και χρησεις
EA200501524A1 (ru) Антитела против амилоида, композиции, способы и применения
CU24058B1 (es) Antagonistas de pcsk9
EA200970131A1 (ru) Миметические антитела для glp-1 человека, композиции, способы и применения
BRPI0921665A2 (pt) humanizado anti-il-6 anticorpos
UY29128A1 (es) Proteinas derivadas de inmunoglobulina específica de il-23p40, composiciones, epitopes, métodos y usos
EA200601603A1 (ru) Миметические антитела glp-1 человека, композиции, способы и применения
MX361533B (es) Anticuerpos anti-cd22.
CO6351748A2 (es) Anticuerpos contra il-6 y sus usos
ECSP14001249A (es) Inmunoenlazadores dirigidos contra el tnf
CR10652A (es) Anticuerpos monoclonales humanos especificos para light humano antagonistas
WO2006085961A3 (en) Anti-mcp-1 antibodies, compositions, methods and uses
BR112013005136A2 (pt) composições e métodos para controlar pragas de nematodeo
AR108975A1 (es) Anticuerpos con baja inmunogenicidad y sus usos
WO2011025883A3 (en) Natural igm antibodies
UY29552A1 (es) Anticuerpos anti-mcp-1, composiciones, métodos y usos
UY29509A1 (es) Anticuerpos anti-il-6, composiciones, métodos y usos
GT200600212A (es) Anticuerpos anti-mcp-1, composiciones, metodos y usos
AR121799A2 (es) Proteínas de unión a antígenos de il-23 humana
BRPI0612728B8 (pt) anticorpos de il-23p19 isolados
AR030133A1 (es) Anticuerpos anti-tnf, composiciones, metodos y usos

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)